Leucovorin

Generic Name
Leucovorin
Brand Names
EnBrace HR, EnLyte, Lederle Leucovorin
Drug Type
Small Molecule
Chemical Formula
C20H23N7O7
CAS Number
58-05-9
Unique Ingredient Identifier
Q573I9DVLP
Background

Folinic Acid (also known as 5-formyl tetrahydrofolic acid or leucovorin) is the 5-formyl derivative of tetrahydrofolic acid, a necessary co-factor in the body. Commercially available leucovorin is composed of a 1:1 racemic mixture of the dextrorotary and levorotary isomers, while levoleucovorin contains only the pharmacologically active levo-isomer. In vitro...

Indication

For the treatment of osteosarcoma (after high dose methotrexate therapy). Used to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists, and to treat megaloblastic anemias due to folic acid deficiency. Also used in combination with 5-fluorouracil to prolong survival in t...

Associated Conditions
Advanced Colorectal Cancer, Advanced Esophageal Cancers, Anemia of Pregnancy, Bladder Cancer, Folate and iron deficiency, Folate deficiency, Folic acid antagonist overdose, Iron Deficiency (ID), Macrocytic anemia, Megaloblastic anemia, Pancreatic Metastatic Cancer, Postpartum Anemia, Stage IV Gastric Cancer, Hypochromic anemia, Methotrexate toxicity, Normochromic anemia, Pyrimethamine hematologic toxicity
Associated Therapies
-
Clinical Trials
Related News

NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer

First Posted Date
2019-07-02
Last Posted Date
2023-12-22
Lead Sponsor
Georgetown University
Target Recruit Count
44
Registration Number
NCT04005339
Locations
🇺🇸

Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, United States

🇺🇸

Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States

🇺🇸

Washington University School of Medicine- Siteman Cancer Center, Saint Louis, Missouri, United States

and more 1 locations

Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer

First Posted Date
2019-06-06
Last Posted Date
2024-01-08
Lead Sponsor
UNC Lineberger Comprehensive Cancer Center
Target Recruit Count
45
Registration Number
NCT03977233
Locations
🇺🇸

University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer

First Posted Date
2019-05-31
Last Posted Date
2024-08-09
Lead Sponsor
Jonsson Comprehensive Cancer Center
Target Recruit Count
28
Registration Number
NCT03970252
Locations
🇺🇸

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

First Posted Date
2019-04-29
Last Posted Date
2024-10-18
Lead Sponsor
Jazz Pharmaceuticals
Target Recruit Count
74
Registration Number
NCT03929666
Locations
🇺🇸

Virginia Mason Medical Center, Seattle, Washington, United States

🇺🇸

H. Lee Moffitt Cancer Center, Tampa, Florida, United States

🇺🇸

USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States

and more 18 locations

Pan Tumor Rollover Study

First Posted Date
2019-04-02
Last Posted Date
2024-11-19
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
1500
Registration Number
NCT03899155
Locations
🇧🇷

Local Institution - 0260, Belo Horizonte, Minas Gerais, Brazil

🇨🇳

Harbin Medical University - Cancer Hospital, Harbin, Heilongjiang, China

🇨🇳

Local Institution - 0172, Changsha, Hunan, China

and more 304 locations

Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy

First Posted Date
2019-03-21
Last Posted Date
2022-10-05
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
20
Registration Number
NCT03883919
Locations
🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1
Terminated
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Anatomic Stage IV Breast Cancer AJCC v8
Anemia
Ann Arbor Stage III Hodgkin Lymphoma
Ann Arbor Stage III Non-Hodgkin Lymphoma
Ann Arbor Stage IV Hodgkin Lymphoma
Ann Arbor Stage IV Non-Hodgkin Lymphoma
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Castration-Resistant Prostate Carcinoma
Interventions
Drug: Abemaciclib
Drug: Abiraterone
Drug: Afatinib
Biological: Bevacizumab
Drug: Bicalutamide
Procedure: Biospecimen Collection
Drug: Bortezomib
Drug: Cabazitaxel
Drug: Cabozantinib
Drug: Capecitabine
Drug: Carboplatin
Drug: Celecoxib
Drug: Cobimetinib
Drug: Copanlisib
Drug: Dabrafenib
Drug: Dacomitinib
Drug: Darolutamide
Drug: Dasatinib
Drug: Doxorubicin
Biological: Durvalumab
Drug: Enasidenib
Drug: Entrectinib
Drug: Enzalutamide
Drug: Erlotinib
Drug: Everolimus
Drug: Fluorouracil
Drug: Idelalisib
Drug: Imatinib
Biological: Ipilimumab
Drug: Lenvatinib
Drug: Leucovorin
Drug: Lorlatinib
Drug: Losartan
Drug: Nab-paclitaxel
Drug: Neratinib
Biological: Nivolumab
Drug: Olaparib
Drug: Oxaliplatin
Drug: Palbociclib
Drug: Panobinostat
Biological: Pembrolizumab
Biological: Pertuzumab
Drug: Ponatinib
Other: Quality-of-Life Assessment
Drug: Regorafenib
Drug: Ruxolitinib
Drug: Sirolimus
Drug: Sorafenib
Drug: Sunitinib
Drug: Trametinib
Biological: Trastuzumab Emtansine
Drug: Tretinoin
Drug: Vemurafenib
Drug: Venetoclax
Drug: Vismodegib
Drug: Vorinostat
First Posted Date
2019-03-18
Last Posted Date
2024-03-04
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
2
Registration Number
NCT03878524
Locations
🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

First Posted Date
2019-03-13
Last Posted Date
2024-08-02
Lead Sponsor
Toray Industries, Inc
Target Recruit Count
187
Registration Number
NCT03872947
Locations
🇺🇸

HOAG Memorial Hospital Presbyterian, Newport, California, United States

🇺🇸

Texas Oncology, P.A. Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States

🇺🇸

Northwest Cancer Specialists, Portland, Oregon, United States

and more 11 locations

Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma

First Posted Date
2019-02-12
Last Posted Date
2023-06-09
Lead Sponsor
The Christie NHS Foundation Trust
Target Recruit Count
102
Registration Number
NCT03837977
Locations
🇬🇧

The Beaston West of Scotland Cancer Center, NHS Greater Glasgow and Clyde, Glasgow, United Kingdom

🇬🇧

Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom

🇬🇧

The Christie NHS Foundation Trust, Manchester, United Kingdom

and more 1 locations

PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

First Posted Date
2019-01-25
Last Posted Date
2024-02-22
Lead Sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Target Recruit Count
31
Registration Number
NCT03817320
Locations
🇺🇸

Texas Children's Hospital/Baylor University, Houston, Texas, United States

🇺🇸

Children's Hospital Orange County, Orange, California, United States

🇺🇸

Cook Children's Medical Center, Fort Worth, Texas, United States

and more 15 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy